CAC 40
7 957,57 +42,92 (+0,54 %) Euro Stoxx 50
4 921,48 +30,87 (+0,63 %) Dow Jones
38 675,68 +450,02 (+1,18 %) EUR/USD
1,0765 +0,0038 (+0,36 %) Gold future
2 310,10 +0,50 (+0,02 %) Bitcoin EUR
59 125,84 -420,11 (-0,71 %)
Molecular Partners AG (MOLN)
Molecular Partners AG
Wagistrasse 14
Schlieren 8952
Switzerland
41 44 755 77 00
https://www.molecularpartners.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 167
Dirigeants clés
| Nom | Titre | Payer | Exercé | Année de naissance |
|---|---|---|---|---|
| Dr. Patrick Amstutz Ph.D. | Co-Founder, CEO, Member of Management Board & Director | 731,34k | S.O. | 1975 |
| Dr. Michael Tobias Stumpp Ph.D. | Co-Founder, Executive VP of Projects & Member of Management Board | S.O. | S.O. | 1972 |
| Mr. Robert Hendriks | Senior VP of Finance | S.O. | S.O. | S.O. |
| Mr. Alexander Zurcher | COO & Member of Management Board | S.O. | S.O. | 1975 |
| Ms. Renate Gloggner | Executive VP of People & Community and Member of Management Board | S.O. | S.O. | 1970 |
| Mr. Daniel Steiner Ph.D. | Senior Vice President of Research & Technology | S.O. | S.O. | S.O. |
| Mr. Seth D. Lewis | Senior Vice President of Investor Relations, Communications & Strategy | S.O. | S.O. | S.O. |
| Mr. Michael Pitzner | General Counsel, Compliance Officer, Senior VP Legal & Business Development | S.O. | S.O. | S.O. |
| Dr. Pamela A. Trail Ph.D. | Strategic Consultant | S.O. | S.O. | 1956 |
| Ms. Anne Goubier D.V.M., Ph.D. | Senior Vice President of Research & Early Development | S.O. | S.O. | S.O. |
Description
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Gouvernance d’entreprise
L’ISS Governance QualityScore de Molecular Partners AG en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..
